Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Griese

Showing results (151-160 of 280) with videos related to

Pageof 28
Sort By:
Expert Review of Respiratory Medicine|April 14, 2015
Pulmonary alveolar proteinosis: time to shift?Spyros A Papiris, Panagiotis Tsirigotis, Likurgos Kolilekas, et al.
BMC Pulmonary Medicine|July 20, 2019
Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)Ekaterina Krauss, Godja Gehrken, Fotios Drakopanagiotakis, et al.
American Journal of Respiratory and Critical Care Medicine|January 17, 2004
Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosisMatthias Griese, Jan Ramakers, Angela Krasselt, et al.
Nature Medicine|December 7, 2007
Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung diseaseDominik Hartl, Philipp Latzin, Peter Hordijk, et al.
Thorax|August 17, 2024
Pulmonary fibrosis may begin in infancy: from childhood to adult interstitial lung diseaseMatthias Griese, Geoffrey Kurland, Michal Cidon, et al.
Pediatric Pulmonology|October 23, 2020
Comorbidity and long-term clinical outcome of laryngotracheal clefts types III and IV: Systematic analysis of new casesElias Seidl, Johanna Kramer, Florian Hoffmann, et al.
ERJ Open Research|March 6, 2024
Single-centre prospective evaluation of the first 5 years of cystic fibrosis newborn screening in GermanyFlorian Gesenhues, Katarzyna Michel, Tobias Greve, et al.
Ebiomedicine|May 8, 2024
A roadmap to precision treatments for familial pulmonary fibrosisKillian Hurley, Mari Ozaki, Quentin Philippot, et al.
Frontiers in Pharmacology|August 19, 2021
Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic FibrosisPatrick O Hanafin, Isabelle Sermet-Gaudelus, Matthias Griese, et al.
Expert Review of Respiratory Medicine|November 13, 2015
Cardiovascular risk in pulmonary alveolar proteinosisEffrosyni D Manali, Georgia Papadaki, Dimitrios Konstantonis, et al.
Pageof 28

Showing results (151-160 of 280) with videos related to

Sort By:
Pageof 28
Expert Review of Respiratory Medicine|April 14, 2015
Pulmonary alveolar proteinosis: time to shift?Spyros A Papiris, Panagiotis Tsirigotis, Likurgos Kolilekas, et al.
BMC Pulmonary Medicine|July 20, 2019
Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)Ekaterina Krauss, Godja Gehrken, Fotios Drakopanagiotakis, et al.
American Journal of Respiratory and Critical Care Medicine|January 17, 2004
Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosisMatthias Griese, Jan Ramakers, Angela Krasselt, et al.
Nature Medicine|December 7, 2007
Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung diseaseDominik Hartl, Philipp Latzin, Peter Hordijk, et al.
Thorax|August 17, 2024
Pulmonary fibrosis may begin in infancy: from childhood to adult interstitial lung diseaseMatthias Griese, Geoffrey Kurland, Michal Cidon, et al.
Pediatric Pulmonology|October 23, 2020
Comorbidity and long-term clinical outcome of laryngotracheal clefts types III and IV: Systematic analysis of new casesElias Seidl, Johanna Kramer, Florian Hoffmann, et al.
ERJ Open Research|March 6, 2024
Single-centre prospective evaluation of the first 5 years of cystic fibrosis newborn screening in GermanyFlorian Gesenhues, Katarzyna Michel, Tobias Greve, et al.
Ebiomedicine|May 8, 2024
A roadmap to precision treatments for familial pulmonary fibrosisKillian Hurley, Mari Ozaki, Quentin Philippot, et al.
Frontiers in Pharmacology|August 19, 2021
Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic FibrosisPatrick O Hanafin, Isabelle Sermet-Gaudelus, Matthias Griese, et al.
Expert Review of Respiratory Medicine|November 13, 2015
Cardiovascular risk in pulmonary alveolar proteinosisEffrosyni D Manali, Georgia Papadaki, Dimitrios Konstantonis, et al.
Pageof 28